Results 61 to 70 of about 5,752,243 (395)

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

New England Journal of Medicine, 2016
BACKGROUND Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in combination
A. Palumbo, A. Chanan-Khan, K. Weisel, A. Nooka, T. Masszi, M. Beksaç, I. Spicka, V. Hungria, M. Munder, M. Mateos, T. Mark, M. Qi, J. Schecter, H. Amin, X. Qin, W. Deraedt, T. Ahmadi, A. Spencer, P. Sonneveld   +18 more
semanticscholar   +1 more source

Phagocytic plasma cells in a patient with multiple myeloma [PDF]

, 1995
Phagocytosis of blood cells by malignant plasma cells in multiple myeloma is an extremely rare condition. Here we present a 39-year-old woman with multiple myeloma.
Hagemeijer, A. (Anne), Leeuw, K. (K.) de, Löwenberg, B. (Bob), Vanhagen, P.M. (P.)   +3 more
core   +1 more source

Autophagy in cancer and protein conformational disorders

FEBS Letters, EarlyView.
Autophagy plays a crucial role in numerous biological processes, including protein and organelle quality control, development, immunity, and metabolism. Hence, dysregulation or mutations in autophagy‐related genes have been implicated in a wide range of human diseases.
Sergio Attanasio
wiley   +1 more source

Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma

Blood Cancer Journal
Multiple myeloma (MM) remains incurable despite novel therapeutics. A major contributor to the development of relapsed/refractory and resistant MM is extraosseous extramedullary disease (EMD), whose molecular biology is still not fully understood.
Rie Nakamoto-Matsubara, Valentina Nardi, Nora Horick, Tsuyoshi Fukushima, Ryan S. Han, Rajib Shome, Kiyosumi Ochi, Cristina Panaroni, Keertik Fulzele, Farah Rexha, Andrew R. Branagan, Diana Cirstea, Andrew J. Yee, David T. Scadden, Noopur S. Raje   +14 more
doaj   +1 more source

Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies [PDF]

, 2016
This is an open-access paper.-- et al.A multistep model has been proposed of disease progression starting in monoclonal gammopathy of undetermined significance continuing through multiple myeloma, sometimes with an intermediate entity called smoldering ...
Bladé, Joan, Corchete, Luis A., Fermiñán, Encarnación, García-Sanz, Ramón, Gutiérrez, Norma Carmen, Hernández, Jesús M., Lahuerta, Juan José, López-Corral, L., Mateos, Maria Victoria, San Miguel, Jesús F., Sarasquete, María Eugenia   +10 more
core   +1 more source

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Development of multiple myeloma in a patient with chronic hepatitis C: A case report and review of the literature [PDF]

, 2006
An association between chronic hepatitis C virus (HCV) infection and essential mixed cryoglobulinaemia and non-Hodgkin lymphoma (NHL) has been suggested. However, a causative role of HCV in these conditions has not been established.
Abonyi, Margit E., Fekete, Sándor, Fischer, Simon, Horányi, Margit, Lakatos, Péter László   +4 more
core   +1 more source

Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation

Molecular Oncology, EarlyView.
Cyclin D1 overexpression altered the cell adhesion pathway, while cyclin D2 upregulation had less impact on pathway enrichment analysis. Multiple myeloma (MM) patients with cyclin D1 overexpression showed reduced CD56 expression and increased circulating tumor cells (CTC) levels, suggesting that cyclin D1 may contribute to MM cell dissemination ...
Ignacio J. Cardona‐Benavides, Sara Cristobal‐Vargas, Cristina De Ramón, Elizabeta A. Rojas, Irena Misiewicz‐Krzeminska, Isabel Isidro, José Juan Pérez, Bruno Paiva, Noemi Puig, Miguel Alcoceba, María‐Victoria Mateos, Luis A. Corchete, Myriam Cuadrado, Norma C. Gutiérrez   +13 more
wiley   +1 more source

Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period

Blood Cancer Journal
The treatment landscape of multiple myeloma (MM) has evolved significantly over four decades, driven by novel therapies and optimized supportive care. However, the attrition rate (AR), defined as the proportion of patients who die without advancing to ...
Luis Gerardo Rodríguez-Lobato, Anna de Daniel, Arturo Pereira, Carlos Fernández de Larrea, Natalia Tovar, M. Teresa Cibeira, David F. Moreno, Jose Miguel Mateos, Noemí Llobet, Esther Carcelero, Daniel Munárriz, Joan Bladé, Laura Rosiñol   +12 more
doaj   +1 more source

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

New England Journal of Medicine, 2016
BACKGROUND Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma.
M. Dimopoulos, A. Oriol, H. Nahi, J. San-Miguel, N. Bahlis, S. Usmani, N. Rabin, R. Orlowski, M. Komarnicki, Kenshi Suzuki, T. Plesner, S. Yoon, D. Ben Yehuda, P. Richardson, H. Goldschmidt, D. Reece, S. Lisby, N. Khokhar, L. O’Rourke, Christopher Chiu, X. Qin, Mary E. Guckert, T. Ahmadi, P. Moreau   +23 more
semanticscholar   +1 more source